BioCentury
ARTICLE | Clinical News

Takeda, Lundbeck get second CRL for Trintellix in MDD

August 16, 2017 8:05 PM UTC

In June, H. Lundbeck A/S (CSE:LUN) and Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) said FDA issued a second complete response letter to an sNDA for Trintellix vortioxetine (Brintellix) to treat cognitive dysfunction in adults with major depressive disorder (MDD). FDA issued the first CRL in 2016...